Evogene
EVGN
Evogene (EVGN) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.14
- EPS estimate
- −$0.27
- EPS surprise
- +48.15%
- Revenue surprise
- +6.77%
- Revenue
- $347,000.00
- Revenue estimate
- $325,000.00
- Reported
- Aug 18, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 18, 2026 | −$0.27 | −$0.14 | +48.15% | $347,000.00 | SEC |
| Q1 2026 | May 20, 2026 | −$0.27 | −$0.60 | −122.22% | $334,000.00 | SEC |
| Q4 2025 | Mar 5, 2026 | −$0.26 | −$0.61 | −134.23% | $314,000.00 | SEC |
| Q3 2025 | Nov 20, 2025 | −$0.41 | $0.44 | +208.39% | $312,000.00 | SEC |
| Q2 2025 | Aug 19, 2025 | −$0.63 | −$0.50 | +20.63% | $884,000.00 | SEC |
| Q1 2025 | May 21, 2025 | −$0.51 | −$0.38 | +24.75% | $2.4M | SEC |
| Q4 2024 | Mar 6, 2025 | −$0.73 | $0.06 | +108.28% | $1.6M | SEC |
| Q3 2024 | Nov 21, 2024 | −$1.01 | −$1.31 | −29.70% | $1.8M | SEC |
| Q2 2024 | Aug 22, 2024 | −$1.25 | −$1.06 | +15.20% | $914,000.00 | SEC |
| Q1 2024 | May 23, 2024 | −$0.95 | −$0.80 | +15.79% | $4.2M | SEC |
| Q4 2023 | Mar 7, 2024 | −$1.40 | −$1.30 | +7.14% | $578,000.00 | SEC |
| Q3 2023 | Nov 15, 2023 | −$1.57 | −$0.80 | +48.94% | $3.8M | SEC |
| Q2 2023 | Aug 17, 2023 | −$1.75 | −$1.70 | +2.86% | $654,000.00 | SEC |
| Q1 2023 | May 18, 2023 | −$1.60 | −$1.50 | +6.25% | $641,000.00 | SEC |
| Q4 2022 | Mar 9, 2023 | −$2.00 | −$0.70 | +65.00% | $660,000.00 | SEC |
| Q3 2022 | Nov 17, 2022 | −$1.97 | −$1.60 | +18.65% | $466,000.00 | — |
| Q2 2022 | Aug 31, 2022 | −$1.90 | −$2.10 | −10.53% | $312,000.00 | — |
| Q1 2022 | May 26, 2022 | −$1.80 | −$2.00 | −11.11% | $237,000.00 | — |
| Q4 2021 | Mar 10, 2022 | −$2.00 | −$1.80 | +10.00% | $311,000.00 | — |
| Q3 2021 | Nov 17, 2021 | −$1.77 | −$1.90 | −7.55% | $151,000.00 | — |
Quarterly revenue
Frequently asked questions
When did Evogene (EVGN) last report earnings?
Evogene last reported on Aug 18, 2026, covering fiscal Q2 2026.
Did EVGN beat earnings estimates?
Yes. Evogene reported EPS of −$0.14 for Q2 2026 against a −$0.27 estimate — a 48.15% beat.
How much revenue did EVGN report last quarter?
Evogene reported $347,000.00 in revenue for Q2 2026, against a consensus estimate of $325,000.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.